|
|
Dr. Bernhard Sixt, Chief Executive Officer (CEO) and founder
Dr. Sixt has extensive experience in the pharmaceutical and diagnostics industry. Before joining Agendia, he was Director of Global Strategic Marketing, Oncology at Amersham Health (now part of GE Healthcare), a world leader in the medical diagnostics market. Dr. Sixt has also held several senior international positions, within product management and global marketing, in Germany, Norway and the UK.
Dr. Bernhard Sixt:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Dr. Laura van 't Veer, Chief Research Officer (CRO) and co-founder
Dr. van 't Veer has a 20-year track record in molecular oncology research with more than 80 papers published in peer-reviewed journals. Within Agendia, Dr. van 't Veer developed the MammaPrint gene expression profiling service and is responsible for the running of the company's central laboratory, for clinical research, and the establishment of new expression profiles. She was head of the Family Cancer Clinic at the Netherlands Cancer Institute (NKI) for 10 years and is currently head of the clinic's DNA-diagnostic laboratory and a staff member in the Department of Molecular Pathology.
Dr. Laura van 't Veer:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Prof. Dr. René Bernards, Chief Scientific Officer (CSO) and co-founder
Prof. Dr. Bernards has a 25-year track record in oncology research with more than 100 papers published in peer-reviewed journals. He has initiated and developed numerous fruitful collaborations with the pharmaceutical industry. As CSO, Prof. Dr. Bernards' responsibility is to explore and implement new technologies as well as developing collaborations with industrial partners. He is head of the division of Molecular Carcinogenesis at the Netherlands Cancer Institute (NKI), which he joined in 1992 after a six-year assistant professorship at Harvard University. He is also a part-time professor of Molecular Carcinogenesis at Utrecht University, The Netherlands.
Prof. Dr. René Berhands:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Kurt Schmidt, Chief Financial Officer (CFO)
Kurt Schmidt:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Dr. Jan Groen, Chief Operating Officer (COO)
Dr. Groen joined Agendia. in 2007, bringing with him more than 20 years of professional experience in the clinical diagnostic industry including IVD diagnostics, pathology services, and pharmaceuticals. Most recently, he served as Vice President Research and Development for Focus Diagnostics Inc. (a subsidiary of Quest Diagnostics Corp.) in California, USA. Dr. Groen has held several international senior leadership positions in product development, clinical trials and laboratory operations.
Dr. Jan Groen:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Dr. Richard Bender, Chief Medical Officer (CMO)
Dr. Bender joined Agendia in 2008, bringing more than 20 years of professional experience in the development of clinical oncology programs and participation in national clinical trials through CALGB, NSABP and pharmaceutical companies while at Kaiser Permanente. More recently, he has pursued his interest in oncology drug development at Spectrum Pharmaceuticals, Quest Diagnostics and Johnson and Johnson. He continues to teach at the UC, Irvine School of Medicine, co-edits the journal Anti-Cancer Drugs and serves as an expert reviewer in oncology for the Medical Board of California. He has authored over 70 peer-reviewed publications and numerous book chapters on topics including malignant lymphoma, pancreatic cancer and the clinical pharmacology of Vinca alkaloids.
Dr. Richard Bender:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
|
|
|
About Agendia